101 related articles for article (PubMed ID: 21137176)
1. [The normalized smoothness index and parametric population RDH index of losartan in patients with newly diagnosed hypertension and metabolic syndrome].
Rihácek I; Frána P; Schwarz D; Plachý M; Soucek M
Vnitr Lek; 2010 Sep; 56(9):901-9. PubMed ID: 21137176
[TBL] [Abstract][Full Text] [Related]
2. [The normalized smoothness index and parametric population RDH index of telmisartane in patients with newly diagnosed hypertension and metabolic syndrome].
Rihácek I; Frána P; Schwarz D; Plachý M; Soucek M
Vnitr Lek; 2010 Jun; 56(6):495-502. PubMed ID: 20681461
[TBL] [Abstract][Full Text] [Related]
3. [The smoothness index of betaxolol hydrochloride in patients with newly diagnosed hypertension].
Rihácek I; Soucek M; Frána P
Vnitr Lek; 2007 Jan; 53(1):25-30. PubMed ID: 17472012
[TBL] [Abstract][Full Text] [Related]
4. Ambulatory monitoring of systolic hypertension in the elderly: Eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST trial).
Ambrosioni E; Bombelli M; Cerasola G; Cipollone F; Ferri C; Grazioli I; Leprotti C; Mancia G; Melzi G; Mugellini A; Mulè G; Palasciano G; Salvetti A; Trimarco B
Adv Ther; 2010 Jun; 27(6):365-80. PubMed ID: 20556561
[TBL] [Abstract][Full Text] [Related]
5. [The safety of long-term administration of losartan in current clinical practice: a non-intervention NCT-CZ 14/04/LOZ study].
Krupicka J; Ceypová K; Kristenová P; Hauser T
Vnitr Lek; 2008 Nov; 54(11):1031-8. PubMed ID: 19069675
[TBL] [Abstract][Full Text] [Related]
6. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials.
Lacourcière Y; Neutel JM; Schumacher H
Clin Ther; 2005 Nov; 27(11):1795-805. PubMed ID: 16368450
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin receptor blockade improves arterial distensibility and reduces exercise-induced pressor responses in obese hypertensive patients with the metabolic syndrome.
Nashar K; Nguyen JP; Jesri A; Morrow JD; Egan BM
Am J Hypertens; 2004 Jun; 17(6):477-82. PubMed ID: 15177518
[TBL] [Abstract][Full Text] [Related]
8. [Estimation of blood pressure, selected biochemical parameters and indices of left ventricular heart function in patients with mild or moderate essential hypertension treated with potassium losartan].
Hrycek A; Badowski R; Scieszka J; Haczkiewicz P; Hefczyc J; Cieślik P
Pol Arch Med Wewn; 2001 Oct; 106(4):891-9. PubMed ID: 11993408
[TBL] [Abstract][Full Text] [Related]
9. Blood pressure effects of the angiotensin II receptor blocker, losartan.
Weber MA; Byyny RL; Pratt JH; Faison EP; Snavely DB; Goldberg AI; Nelson EB
Arch Intern Med; 1995 Feb; 155(4):405-11. PubMed ID: 7848024
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of long-term losartan therapy demonstrated by a prospective observational study in Japanese patients with hypertension: The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study.
Naritomi H; Fujita T; Ito S; Ogihara T; Shimada K; Shimamoto K; Tanaka H; Yoshiike N
Hypertens Res; 2008 Feb; 31(2):295-304. PubMed ID: 18360050
[TBL] [Abstract][Full Text] [Related]
11. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Hypertension: Favourable Effect of the Twice-Daily Compared to the Once-Daily (Evening) Administration of Perindopril and Losartan.
Szauder I; Csajági E; Major Z; Pavlik G; Ujhelyi G
Kidney Blood Press Res; 2015; 40(4):374-85. PubMed ID: 26160625
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility and applicability of smoothness index, normalized smoothness index and individualized RDH index during treatment of essential hypertension.
Stenehjem AE; Os I
Blood Press; 2006; 15(5):281-90. PubMed ID: 17380846
[TBL] [Abstract][Full Text] [Related]
14. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients.
Kintscher U; Bramlage P; Paar WD; Thoenes M; Unger T
Cardiovasc Diabetol; 2007 Apr; 6():12. PubMed ID: 17407587
[TBL] [Abstract][Full Text] [Related]
15. Antihypertensive and renoprotective efficacy and safety of losartan. A long-term study in children with renal disorders.
Ellis D; Moritz ML; Vats A; Janosky JE
Am J Hypertens; 2004 Oct; 17(10):928-35. PubMed ID: 15485756
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
[TBL] [Abstract][Full Text] [Related]
17. Effect of combination therapy with the angiotensin receptor blocker losartan plus hydrochlorothiazide on brain perfusion in patients with both hypertension and cerebral hemodynamic impairment due to symptomatic chronic major cerebral artery steno-occlusive disease: a SPECT study.
Saura H; Ogasawara K; Suzuki T; Kuroda H; Yamashita T; Kobayashi M; Terasaki K; Ogawa A
Cerebrovasc Dis; 2012; 33(4):354-61. PubMed ID: 22433127
[TBL] [Abstract][Full Text] [Related]
18. Effect of losartan on ambulatory short-term blood pressure variability and cardiovascular remodeling in hypertensive patients on hemodialysis.
Mitsuhashi H; Tamura K; Yamauchi J; Ozawa M; Yanagi M; Dejima T; Wakui H; Masuda S; Azuma K; Kanaoka T; Ohsawa M; Maeda A; Tsurumi-Ikeya Y; Okano Y; Ishigami T; Toya Y; Tokita Y; Ohnishi T; Umemura S
Atherosclerosis; 2009 Nov; 207(1):186-90. PubMed ID: 19423110
[TBL] [Abstract][Full Text] [Related]
19. [An experience of the use of angiotensin II receptor blocker losartan in patients with metabolic syndrome and chronic kidney disease].
Beloborodova AV; Morozova TE; Shilov EM
Kardiologiia; 2010; 50(8):32-6. PubMed ID: 21105327
[TBL] [Abstract][Full Text] [Related]
20. Effects of angiotensin II receptor blockade-based therapy with losartan on left ventricular hypertrophy and geometry in previously treated hypertensive patients.
Cuspidi C; Meani S; Valerio C; Fusi V; Sala C; Maisaidi M; Zanchetti A
Blood Press; 2006; 15(2):107-15. PubMed ID: 16754274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
